|
1
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S and Palmerini E: Adjuvant and
neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr
Opin Oncol. 19:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Panda S, Choudhary K, Srivastava G,
Padhiary SK, Dhull KS and Sanghavi D: An Indian perspective on
gnathic osteosarcoma: A comprehensive literature review of the last
three decades. J Oral Maxillofac Surg Med Pathol. 26:198–206. 2014.
View Article : Google Scholar
|
|
6
|
Picci P: Osteosarcoma (Osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosen G: Neoadjuvant chemotherapy for
osteogenic sarcoma: A model for the treatment of other highly
malignant neoplasms. Recent Results Cancer Res. 103:148–157. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: An update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165.
2003.PubMed/NCBI
|
|
9
|
Niu BH, Wang JJ, Xi Y and Ji XY: The
establishment and characterization of adriamycin-resistant cell
lines derived from Saos-2. Med Sci Monit. 16:BR184–BR192.
2010.PubMed/NCBI
|
|
10
|
Okugawa K, Kobayashi H, Hirakawa T, Sonoda
T, Ogura T and Nakano H: In vivo establishment and characterization
of a paclitaxel-resistant human ovarian cancer cell line showing
enhanced growth properties and drug-resistance only in vivo. J
Cancer Res Clin Oncol. 130:178–186. 2004. View Article : Google Scholar
|
|
11
|
Kanzawa F, Sugimoto Y, Minato K, Kasahara
K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N:
Establishment of a camptothecin analogue (CPT-11)-resistant cell
line of human non-small cell lung cancer: Characterization and
mechanism of resistance. Cancer Res. 50:5919–5924. 1990.PubMed/NCBI
|
|
12
|
Negoro K, Yamano Y, Fushimi K, Saito K,
Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, et al:
Establishment and characterization of a cisplatin-resistant cell
line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol.
30:1325–1332. 2007.PubMed/NCBI
|
|
13
|
Swanton C: Intratumor heterogeneity:
Evolution through space and time. Cancer Res. 72:4875–4882. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almendro V, Marusyk A and Polyak K:
Cellular heterogeneity and molecular evolution in cancer. Annu Rev
Pathol. 8:277–302. 2013. View Article : Google Scholar
|
|
15
|
McGranahan N and Swanton C: Biological and
therapeutic impact of intratumor heterogeneity in cancer evolution.
Cancer Cell. 27:15–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burrell RA, McGranahan N, Bartek J and
Swanton C: The causes and consequences of genetic heterogeneity in
cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barteneva NS, Ketman K, Fasler-Kan E,
Potashnikova D and Vorobjev IA: Cell sorting in cancer
research-diminishing degree of cell heterogeneity. Biochim Biophys
Acta. 1836:105–122. 2013.PubMed/NCBI
|
|
18
|
Zhang H, Wang Y, Xing F, Wang J, Wang Y,
Wang H, Yang Y and Gao Z: Overexpression of LIMK1 promotes
migration ability of multidrug-resistant osteosarcoma cells. Oncol
Res. 19:501–509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Zhang X, Peng X, Yu W, Hou S, Zhao Y,
Zhang Z, Huang X and Wu K: Alpha-tocopheryl succinate enhances
doxorubicin-induced apoptosis in human gastric cancer cells via
promotion of doxorubicin influx and suppression of doxorubicin
efflux. Cancer Lett. 307:174–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Souhami RL, Craft AW, Van der Eijken JW,
Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ,
Kirkpatrick A, Uscinska BM, et al: Randomised trial of two regimens
of chemotherapy in operable osteosarcoma: A study of the European
Osteosarcoma Intergroup. Lancet. 350:911–917. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cerezo D, Cánovas M, García-Peñarrubia P
and Martín-Orozco E: Collateral sensitivity to cold stress and
differential BCL-2 family expression in new daunomycin-resistant
lymphoblastoid cell lines. Exp Cell Res. 331:11–20. 2015.
View Article : Google Scholar
|
|
25
|
Takeshita H, Kusuzaki K, Ashihara T,
Gebhardt MC, Mankin HJ and Hirasawa Y: Intrinsic resistance to
chemotherapeutic agents in murine osteosarcoma cells. J Bone Joint
Surg Am. 82-A:963–969. 2000.PubMed/NCBI
|
|
26
|
Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo
KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis
of the EC109/CDDP multidrug-resistant esophageal squamous cell
carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
|
|
27
|
Park J, Bae EK, Lee C, Choi JH, Jung WJ,
Ahn KS and Yoon SS: Establishment and characterization of
bortezomib-resistant U266 cell line: Constitutive activation of
NF-kB-mediated cell signals and/or alterations of
ubiquitylation-related genes reduce bortezomib-induced apoptosis.
BMB Rep. 47:274–279. 2014. View Article : Google Scholar :
|
|
28
|
Gerlinger M and Swanton C: How Darwinian
models inform therapeutic failure initiated by clonal heterogeneity
in cancer medicine. Brit J Cancer. 103:1139–1143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kars MD, Işeri ÖD and Gündüz U: A
microarray based expression profiling of paclitaxel and vincristine
resistant MCF-7 cells. Eur J Pharmacol. 657:4–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Q, Jiao D, Hu H, Song J, Yan J, Wu L
and Xu LQ: Downregulation of LIMK1 level inhibits migration of lung
cancer cells and enhances sensitivity to chemotherapy drugs. Oncol
Res. 20:491–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou Y, Su J, Shi L, Liao Q and Su Q: DADS
downregulates the Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin signaling
pathway, inhibiting cell migration and invasion. Oncol Rep.
29:605–612. 2013.
|
|
32
|
Zhang HS, Zhao JW, Wang H, Zhang HY, Ji
QY, Meng LJ, Xing FJ, Yang ST and Wang Y: LIM kinase 1 is required
for insulin-dependent cell growth of osteosarcoma cell lines. Mol
Med Rep. 9:103–108. 2014.
|
|
33
|
Yan XD, Li M, Yuan Y, Mao N and Pan LY:
Biological comparison of ovarian cancer resistant cell lines to
cisplatin and Taxol by two different administrations. Oncol Rep.
17:1163–1169. 2007.PubMed/NCBI
|
|
34
|
Li L, Luan Y, Wang G, Tang B, Li D, Zhang
W, Li X, Zhao J, Ding H, Reed E and Li QQ: Development and
characterization of five cell models for chemoresistance studies of
human ovarian carcinoma. Int J Mol Med. 14:257–264. 2004.PubMed/NCBI
|
